查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1847723

气喘药物市场按产品类型、药物类别、通路、给药途径和最终用户划分－2025-2032 年全球预测

Asthma Therapeutics Market by Product Type, Drug Class, Distribution Channel, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年气喘药物市场规模将成长至 626.7 亿美元，复合年增长率为 10.96%。

主要市场统计数据
基准年2024年 272.6亿美元
预计2025年 303.2亿美元
预测年份：2032年 626.7亿美元
复合年增长率（%） 10.96%

重塑气喘药物和病患照护途径的临床、监管和商业性力量融合的简明框架

气喘药物领域正进入一个新阶段，临床创新、设备革新和医疗保健系统的压力正在汇聚，重新定义针对各年龄层患者的医疗服务。生物製药的进步治疗方法改变重度、未控制气喘的治疗模式，吸入器和雾化器技术的不断改进也持续影响常规治疗。同时，支付方和医疗保健提供者要求提供现实世界疗效和成本效益的明确证据，这迫使製造商重新思考其商业化和证据产生策略。

因此，相关人员必须在科学突破与实际运作之间找到平衡。监管途径正在发生变化，以适应新型生物製药和组合药物药物，供应链也在适应影响原料采购和生产布局的地缘政治和贸易动态。如今，临床医生和看护者期待将治疗手段与增强依从性的设备和数位监控相结合的综合解决方案。

本引言概述了影响治疗方法选择、设备采用和相关人员行为的核心动态。它强调了创新、报销和提供者工作流程之间的相互作用如何决定竞争优势，为深入分析本报告中涵盖的转型变化、资费影响、细分考虑和区域洞察奠定了基础。

深入探讨生技药品、设备融合、付款人需求和不断变化的法规如何改变气喘治疗和商业化

气喘药物领域正在经历一场变革，其驱动力来自治疗方法专业化、设备整合、支付方审查以及数位化赋能。针对特定免疫途径的生物製药正从小众用途转向重症气喘管理的核心角色，这迫使护理团队采用依赖生物标记检测和专科转诊网路的精准医疗方法。同时，吸入器和雾化器技术改进了剂量和易用性，鼓励长期坚持用药，并结合患者教育倡议，减少了急性护理事件。

同时，付款人和医疗保健系统要求更强有力的价值叙述，这迫使他们展示超越传统临床终点的疗效。这加速了真实世界证据和卫生经济分析作为打入市场策略核心要素的应用。此外，设备和治疗方法的融合正在催生新的商业模式，其中药物-设备组合和数位化依从性平台是差异化因素。将吸入式设备与连网监测工具结合的製造商可以改善临床疗效，同时透过提供服务创造新的收益来源。

最后，监管机构正在重新调整核准和上市后预期，以适应组合药物和生物製药日益复杂的现状。这些监管变革，加上对以病人为中心的医疗服务的日益重视，正在重塑商业性时间表和临床开发方法。最终结果是，市场将鼓励跨学科创新、协作证据产生和敏捷的商业化策略。

全面分析美国2025 年关税格局及其对製造选择、供应弹性和商业策略的下游影响。

美国将于2025年生效的新关税和贸易措施，要求对整个气喘药物生态系统进行策略性评估，其累积影响取决于产品复杂性和供应链依赖程度。依赖进口零件、专用辅料和成品的企业正因投入成本上升而面临利润压力，迫使它们重新协商供应商合约。生技药品製造商通常依赖复杂、高价值的供应链和低温运输物流，因此尤其面临风险，因为生产连续性和品管至关重要，且难以轻易转移。

同时，专业医疗设备製造商受到奖励，加快在岸化生产并实现零件采购多元化，以缓解关税造成的成本波动。这一趋势推动了对国内製造产能的投资增加、与合约开发和製造机构的合作以及流程自动化，以降低劳动强度。付款人和采购团队对此作出了回应，他们收紧了处方标准，并加强了成本控制谈判，迫使製造商提供更有力的比较有效性证据，并考虑创新定价。

贸易措施也影响了核准提交和上市时间，这对拥有垂直整合供应链和健全紧急时应对计画的公司有利。因此，这些公司的策略性应对措施包括加速本地生产、重新设计包装和零件采购以避免关税分类，以及建立策略联盟以共用製造风险。这些措施有助于保持竞争优势，同时确保临床医生和患者的药品供应连续性。

整合按产品类型、药品类别、分销管道、给药途径和最终用户群体进行的详细细分，以指导策略定位

准确的细分视角对于了解临床价值和机会在产品类型、给药途径、分销管道、药物类别和最终用户群之间的交集至关重要。根据产品类型，我们将生物製药，生物製药将干粉、定量和缓雾吸入器嗜酸性粒细胞，每种吸入器都提供不同的性能特征和依从性。雾化器细分为喷射式、网状式和超音波雾化器，易用性、粒度控制和便携性决定了临床应用。口服药物包括白三烯调节剂、口服类固醇和茶碱，每种药物根据严重程度、合併症情况和耐受性考虑占据特定的市场。

依药物类别细分，透过区分β受体促效剂、联合治疗、吸入性皮质类固醇、白三烯调节剂和单株抗体，进一步明确了治疗选择的驱动因素。每个类别都与特定的疾病严重程度和指南建议一致，影响处方模式和处方放置。分销管道细分揭示了医生办公室、医院药房、网路药房和零售药房之间在获取药物和病患体验方面的差异。医生办公室类别包括居家照护机构和门诊诊所，它们的给药模式和报销途径有显着不同。给药途径细分捕获了吸入、口服和肠外途径之间的临床和后勤权衡，其中吸入分为气雾剂和粉剂，口服静脉注射和皮下途径，影响临床医生的参与、监测要求和患者偏好。

终端用户细分将人口统计需求分为成人、老年人和儿童。老年人群进一步细分为65-74岁和75岁以上，以适应功能性用药和多种药物治疗的需求；而儿童人群则细分为0-5岁和6-12岁，以适应设备适用性、剂量限制和看护者支持需求的差异。结合这些细分观点，可以更细緻地观点产品定位、临床试验设计、报销策略和市场执行情况，并使其与实际治疗途径和相关人员的期望一致。

有关美洲、欧洲、中东和非洲以及亚太地区的市场准入、监管复杂性和采用动态的区域信息

美洲、欧洲、中东和非洲以及亚太地区的区域动态正在影响产品开发、监管策略和商业化重点。在美洲，先进的专科护理网络和生物製药支撑了重症气喘的快速增长，但日益增长的支付方成熟度和成本控制压力需要强有力的卫生经济证据和战略性合约。因此，优先考虑美洲市场的製造商越来越重视疗效数据、专科药房合作伙伴关係以及减少行政摩擦和提高依从性的患者支援模式。

欧洲、中东和非洲地区法规和付款人制度各异，因此市场准入计画必须考虑到各国医疗技术评估 (HTA) 流程、采购架构和报销标准的差异。在这些市场运营的製造商通常会建立本地临床註册库和真实世界证据项目，以证明其在当地环境下的价值，同时投资于适应竞标和参考定价机制的定价策略。部分地区产能受限，可能需要建立更强大的经销伙伴并开展培训项目，以确保器械的妥善处理和管理。

亚太地区呈现出多元化的格局，快速的医疗现代化与不稳定的基础设施和可近性并存。在某些市场，大规模学名药製造商和不断发展的生物技术产业带来了激烈的竞争；而在其他市场，不断扩展的诊断能力和专科护理正在推动对先进疗法的需求。瞄准亚太地区的开发商通常会在密集的临床开发与本地化的监管要求之间取得平衡，探索分阶段的产品供应和本地化製造地，以控製成本并缩短前置作业时间。在所有地区，本地化的病人参与和临床医生教育仍然是成功实施的关键。

创新者、设备专家、非专利供应商和製造合作伙伴的策略竞争概述，塑造产品差异化和市场进入

气喘治疗领域的竞争态势体现在创新生物製药开发商、传统吸入器和雾化器製造商、学名药和口服药物供应商以及新兴设备技术参与企业之间的互补作用。专注于单株抗体的创新者正透过生物标记主导的适应症、生命週期策略以及向表型特异性人群的扩展来推动差异化发展。这些公司也投资于伴随诊断和专业通路，以优化患者选择和依从性。

设备製造商持续在交付能力、用户人体工学以及与数位依从性平台的整合方面展开竞争，并与製药公司伙伴关係，提供差异化的药械组合。学名药和口服药物製造商注重成本效益和广泛的可用性，经常利用庞大的製造和分销网络为基层医疗管道提供服务。同时，合约开发和受託製造厂商以及设备组件供应商是关键的推动者，他们提供的产能和技术专长会影响产品上市速度和在岸营运的可行性。

整体而言，公司策略强调尽可能进行垂直整合，建立策略联盟以补充核心竞争力，并进行有针对性的收购以确保设备专业知识和生物製剂产品线。将临床创新与强大的商业性执行力、证据产生能力和供应链韧性相结合的公司，能够更好地规避付款方审查，并充分利用不断变化的临床指南和患者期望。

製造商需要采取切实可行的策略措施，协调临床证据、设备整合、供应弹性和市场进入，以获得竞争优势

产业领导者应采取一系列切实可行的策略，将临床价值与营运韧性和商业性敏捷性结合。首先，优先考虑证据生成，包括真实世界数据和患者报告结果，而不仅仅是随机试验。其次，在开发早期整合设备和数位化能力，创建配套服务模式，以提高依从性，提供可操作的患者数据，并占据高端市场。

第三，透过地理多元化、策略性製造外包以及在关税和物流风险不可接受的情况下选择性地在岸外包，优化您的供应链。透过立即重新规划您的采购和製造布局，企业可以降低贸易波动带来的脆弱性，并维持产品上市计画。第四，透过投资卫生经济学、成果研究和当地相关人员的参与，制定适合当地监管和报销环境的打入市场策略。

最后，我们将寻求有针对性的合作，包括共同开发、授权和商业联盟，以利用生技药品、设备工程、数位健康等领域的互补能力。此类伙伴关係可加速市场进入，共用开发风险，并扩大治疗生态系统。实施这些建议需要跨职能管治、明确的关键绩效指标 (KPI) 和增量投资，以使研发、商业和製造目标与不断变化的市场现实保持一致。

透过结合临床专家访谈、二手文献综合、供应链映射和情境分析的严格混合方法研究途径获得可靠的见解

本分析整合了原始研究和二手研究，旨在为策略决策提供可靠且检验的依证。原始研究包括与呼吸系统医疗设备和过敏科临床关键意见领袖进行结构化咨询、与各治疗和器械领域的商业高管进行访谈，以及与采购和付款人代表进行咨询，以了解报销优先级和签约趋势。这些调查提供了关于临床医生偏好、患者依从性驱动因素以及商业性决策框架的定性见解。

二次调查全面回顾了同行评审的临床文献、监管指南文件以及描述治疗机制、设备性能特征和安全注意事项的行业出版物。供应链图谱和资费分类分析确定了薄弱环节，并评估了潜在的缓解策略。对观察结果和次要研究观察进行三角检验，确保了临床、商业和营运方面的一致性。

分析方法包括比较产品定位分析、针对关税和供应链中断的情境规划，以及细分主导的评估，以确保产品属性与最终用户和分销管道的需求相符。品管方法包括访谈结果的交叉检验、监管和临床文献的资讯来源检验，以及用于完善结论的迭代同行评审。这些方法的结合，为规划产品开发、市场准入和策略投资的相关人员提供了令人信服且切实可行的见解。

执行总结强调了对综合临床证据、设备创新、弹性供应链和客製化存取策略的需求

总而言之，气喘治疗领域蕴藏着一系列复杂且易于掌握的机会，而这得益于临床创新与务实的商业和营运策略的结合。生物製药正在重新定义严重表型患者的治疗，而设备和数位化技术的进步则正在提高依从性并支持新的基于价值的模式。然而，诸如付款人审查和贸易相关关税变化等外部压力要求我们在证据生成、供应链设计和定价策略方面做出适应性应对。

成功的相关人员能够整合跨学科能力，例如开发强大的真实世界证据专案、以使用者为中心的设备设计以及建立富有弹性的製造布局。投资伙伴关係，无论是与设备工程师、契约製造或区域经销商，都能加速市场进入并降低执行风险。此外，根据当地监管和报销情况制定策略，可以提升不同市场的可及性和商业性绩效。

这项结论强调，研发、商业和营运团队必须齐心协力，将科学进步转化为永续的病患效益和商业性回报。那些积极主动地重视证据、整合和韧性的组织，将最有能力引领不断发展的气喘治疗生态系统。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 标籤扩展后生物製剂治疗重度嗜酸性粒细胞气喘的长期安全性和有效性的真实世界证据
  • 将数位吸入器与远端医疗平台结合，可提高儿童和成人气喘患者的用药依从性和监测能力
  • 开发小分子 CRTh2 受体拮抗剂作为治疗中度至重度气喘的新型口服治疗药物
  • 探索个人化气喘治疗流程，结合基因组和生物标记分析数据来选择生物目标
  • ICS、LABA 和 LAMA 三联吸入器疗法在改善未控制气喘患者控制方面的进展
  • FDA 和 EMA 近期扩大 tezepelumab 和 dupilumab 的适应症范围对全球气喘治疗策略的监管影响
  • 抗 TSLP 和抗 IL-25 候选药物的出现及其重新定义重度气喘治疗方案的潜力

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章气喘药物市场（依产品类型）

  • 生物製药
    • 抗IgE
    • 抗IL5
  • 吸入器
    • 干粉吸入器
    • 定量喷雾吸入器
    • 缓雾吸入器
  • 喷雾器
    • 喷射雾化器
    • 网状雾化器
    • 超音波雾化器
  • 口服药物
    • 白三烯调节剂
    • 口服类固醇
    • 茶碱

第九章气喘药物市场（依药物类别）

  • β-促效剂
  • 联合治疗
  • 吸入性皮质类固醇
  • 白三烯调节剂
  • 单株抗体

第 10 章气喘药物市场（依分销管道）

  • 诊所
    • 居家照护环境
    • 门诊
  • 医院药房
  • 网路药局
  • 零售药局

第 11 章气喘药物市场（依给药途径）

  • 吸入
    • 气雾剂
    • 粉末
  • 口服
    • 糖浆状
    • 药片
  • 肠外
    • 静脉
    • 皮下

第 12 章气喘药物市场（依最终使用者）

  • 成人
  • 老年人
    • 65-74岁
    • 75岁或以上
  • 孩子们
    • 0至5岁
    • 6至12岁

第十三章气喘药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章气喘药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各国气喘药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • GlaxoSmithKline plc
    • AstraZeneca PLC
    • Teva Pharmaceutical Industries Limited
    • Novartis AG
    • Sanofi SA
    • Boehringer Ingelheim International GmbH
    • Viatris Inc.
    • Sunovion Pharmaceuticals Inc.
    • Chiesi Farmaceutici SpA
    • Cipla Limited
Product Code: MRR-AB49FC1AB810

The Asthma Therapeutics Market is projected to grow by USD 62.67 billion at a CAGR of 10.96% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 27.26 billion
Estimated Year [2025] USD 30.32 billion
Forecast Year [2032] USD 62.67 billion
CAGR (%) 10.96%

A concise framing of the converging clinical, regulatory, and commercial forces reshaping asthma therapeutics and patient care pathways

The asthma therapeutics environment is entering a phase where clinical innovation, device evolution, and health system pressures converge to redefine care delivery for patients across age groups. Advances in biologic therapies have shifted treatment paradigms for severe and uncontrolled asthma, while incremental improvements in inhaler and nebulizer technology continue to shape everyday management. At the same time, payers and providers are demanding clearer evidence of real-world effectiveness and cost utility, prompting manufacturers to rethink commercialization and evidence-generation strategies.

As a result, stakeholders must navigate a landscape that balances scientific breakthroughs with operational realities. Regulatory pathways are adapting to accommodate novel biologic modalities and combination products, and supply chains are adjusting to geopolitical and trade dynamics that affect component sourcing and manufacturing footprints. Clinicians and caregivers now expect integrated solutions that couple therapeutics with adherence-enhancing devices and digital monitoring, which in turn forces manufacturers to develop cross-functional capabilities in product development, data analytics, and patient support programs.

This introduction frames the core dynamics influencing therapy selection, device adoption, and stakeholder behavior. It clarifies how the interplay between innovation, reimbursement, and provider workflows will determine competitive advantage, and sets the stage for deeper analysis of transformative shifts, tariff impacts, segmentation insights, and regional considerations included in this report.

Detailed exploration of how biologics, device convergence, payer demands, and regulatory evolution are collectively transforming asthma care and commercialization

The landscape for asthma therapeutics is undergoing transformative shifts driven by therapeutic specialization, device integration, payer scrutiny, and digital augmentation. Biologic therapies targeting specific immunological pathways have moved from niche applications to central roles in the management of severe asthma, compelling care teams to adopt precision medicine approaches that rely on biomarker testing and specialist referral networks. Concurrently, inhaler and nebulizer technologies have improved dose delivery and usability, encouraging longer-term adherence and reducing acute care episodes when paired with patient education initiatives.

In parallel, payers and health systems are demanding stronger value narratives, creating pressure to demonstrate outcomes beyond traditional clinical endpoints. This has accelerated the use of real-world evidence and health economics analyses as core components of market access strategies. Moreover, device-therapy convergence is fostering new commercial models where drug-device combinations and digital adherence platforms become differentiators. Manufacturers that integrate inhalation devices with connected monitoring tools stand to improve clinical outcomes while creating new revenue streams through service offerings.

Finally, regulatory agencies are recalibrating approval and post-market surveillance expectations to match the complexity of combination products and biologics. This regulatory evolution, combined with an emphasis on patient-centric care, is reshaping commercial timelines and clinical development approaches. The net effect is a market that rewards cross-disciplinary innovation, collaborative evidence generation, and nimble commercialization strategies.

Comprehensive analysis of the United States 2025 tariff landscape and its downstream effects on manufacturing choices, supply resilience, and commercial strategies

The introduction of new tariffs and trade measures in the United States in 2025 has prompted a strategic reassessment across the asthma therapeutics ecosystem, with cumulative impacts that vary by product complexity and supply chain dependence. Companies that rely on imported components, specialized excipients, or finished devices have experienced escalated input costs that compress margins and prompt renegotiation of supplier contracts. Manufacturers of biologics, which often depend on complex, high-value supply chains and cold-chain logistics, face particular exposure because production continuity and quality control are critical and not easily relocated.

On the other hand, device-focused producers have had incentives to accelerate onshoring or diversify component sourcing to mitigate tariff-driven cost volatility. This trend has driven increased investment in domestic manufacturing capacity, contract development and manufacturing organization partnerships, and process automation to reduce labor intensity. Payers and procurement teams have responded by tightening formulary criteria and intensifying cost-containment negotiations, which pressures manufacturers to present stronger evidence of comparative effectiveness and to consider innovative pricing arrangements.

Trade measures have also affected timelines for regulatory submissions and launch sequencing in ways that favor companies with vertically integrated supply chains or robust contingency planning. As a result, strategic responses have included accelerating local production, redesigning packaging and component sourcing to avoid tariff classifications, and pursuing strategic alliances to share manufacturing risk. These approaches help preserve competitive positioning while maintaining continuity of supply for clinicians and patients.

In-depth segmentation synthesis describing product types, drug classes, distribution channels, routes of administration, and end-user cohorts to guide strategic positioning

A precise segmentation lens is essential to understand where clinical value and commercial opportunity intersect across product types, administration routes, distribution pathways, drug classes, and end-user cohorts. Product type segmentation differentiates Biologics from Inhalers, Nebulizers, and Oral Drugs; within Biologics the focus is on antibody therapies such as anti-IgE and anti-IL-5 agents that address eosinophilic and allergic phenotypes, while Inhalers are parsed into Dry Powder Inhalers, Metered Dose Inhalers, and Soft Mist Inhalers, each offering distinct performance characteristics and adherence implications. Nebulizers are subdivided into Jet Nebulizers, Mesh Nebulizers, and Ultrasonic Nebulizers, with usability, particle size control, and portability shaping clinical adoption. Oral Drugs encompass Leukotriene Modifiers, Oral Corticosteroids, and Theophylline, which occupy specific niches based on severity, comorbidity profiles, and tolerability considerations.

Drug class segmentation further clarifies therapy selection drivers by distinguishing Beta Agonists, Combination Therapies, Inhaled Corticosteroids, Leukotriene Modifiers, and Monoclonal Antibodies; each class aligns with particular disease severities and guideline recommendations, influencing prescribing patterns and formulary placement. Distribution channel segmentation highlights variations in access and patient experience across Clinics, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, and the Clinics category includes Home Care Settings and Outpatient Clinics where administration models and reimbursement pathways differ substantially. Route of administration segmentation captures the clinical and logistical trade-offs among Inhalation, Oral, and Parenteral routes; inhalation itself breaks into Aerosol and Powder formats, oral presentations include Syrup Form and Tablet Form, and parenteral delivery is separated into Intravenous and Subcutaneous approaches that affect clinician involvement, monitoring requirements, and patient preference.

End-user segmentation frames demographic-driven demand across Adult, Geriatric, and Pediatric populations; the Geriatric cohort is further divided into 65-74 Years and 75 Plus Years to reflect functional and polypharmacy considerations, while the Pediatric cohort is split into 0-5 Years and 6-12 Years to account for differences in device suitability, dosing constraints, and caregiver support needs. Taken together, these segmentation perspectives enable a nuanced view of product positioning, clinical trial design, reimbursement strategy, and go-to-market execution that aligns with real-world treatment pathways and stakeholder expectations.

Regional intelligence on access, regulatory complexity, and adoption dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets

Regional dynamics shape priorities for product development, regulatory strategy, and commercialization, with distinct opportunities and constraints across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, advanced specialty care networks and widespread availability of biologic therapies support rapid adoption for severe asthma, yet payer sophistication and cost-containment pressures require robust health economic evidence and strategic contracting. As a result, manufacturers prioritizing the Americas tend to emphasize outcomes data, specialty pharmacy partnerships, and patient support models that reduce administrative friction and improve adherence.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse payer systems necessitate tailored market access plans that account for national HTA processes, procurement frameworks, and differing reimbursement criteria. Manufacturers operating across these markets often deploy regional clinical registries and real-world evidence programs to demonstrate value in local contexts, while also investing in pricing strategies adaptable to tendering and reference pricing mechanisms. Capacity constraints in parts of the region can create demand for more robust distribution partnerships and training programs to ensure proper device handling and administration.

The Asia-Pacific region presents a multifaceted picture where rapid healthcare modernization coexists with variable infrastructure and access. In certain markets, high-volume generics producers and a growing biotech sector drive intense competition, while other markets show rising demand for advanced therapies as diagnostic capabilities and specialty care expand. Manufacturers targeting Asia-Pacific frequently balance centralized clinical development with localized regulatory engagement, and they explore tiered product offerings and regional manufacturing hubs to manage cost and improve lead times. Across all regions, localized patient engagement and clinician education remain central to successful adoption.

Strategic competitive overview of innovators, device specialists, generic suppliers, and manufacturing partners shaping product differentiation and market entry

Competitive dynamics in asthma therapeutics are characterized by complementary roles played by innovative biologic developers, legacy inhaler and nebulizer manufacturers, generic and oral therapy suppliers, and emerging device-tech entrants. Innovator companies that specialize in monoclonal antibodies are driving differentiation through biomarker-driven indications, lifecycle strategies, and label expansions into phenotype-specific populations. These firms also invest in companion diagnostics and specialty distribution pathways to optimize patient selection and adherence.

Device manufacturers continue to compete on deliverability, user ergonomics, and integration with digital adherence platforms, forging partnerships with pharmaceutical companies to offer differentiated drug-device combinations. Generic players and manufacturers of oral therapies focus on cost-effectiveness and wide availability, frequently leveraging scale manufacturing and distribution networks to serve primary-care channels. Meanwhile, contract development and manufacturing organizations and device component suppliers are crucial enablers, providing capacity and technical expertise that influence speed to market and the feasibility of onshoring initiatives.

Collectively, company strategies emphasize vertical integration where feasible, strategic partnerships to complement core capabilities, and targeted acquisition to secure device know-how or biologic pipelines. Organizations that combine clinical innovation with strong commercial execution, evidence generation, and supply chain resilience are better positioned to navigate payer scrutiny and to capitalize on evolving clinical guidelines and patient expectations.

Actionable strategic imperatives for manufacturers to align clinical evidence, device integration, supply resilience, and market access for competitive advantage

Industry leaders should adopt a set of pragmatic, actionable strategies that align clinical value with operational resilience and commercial agility. First, prioritize evidence generation that extends beyond randomized trials to include real-world data and patient-reported outcomes; this will strengthen value propositions in payer negotiations and support uptake among clinicians who require proof of effectiveness in routine care. Second, integrate device and digital capabilities early in development to enhance adherence, provide actionable patient data, and create bundled service models that can command premium positioning.

Third, optimize supply chains through geographic diversification, strategic contract manufacturing partnerships, and selective onshoring where tariff exposure or logistics risk is unacceptable. By redesigning sourcing and manufacturing footprints now, companies can reduce vulnerability to trade volatility and preserve launch timelines. Fourth, tailor market access strategies to regional regulatory and reimbursement environments by investing in health economics, outcomes research, and local stakeholder engagement; this ensures that pricing and contracting reflect regional payer priorities and clinical practice.

Finally, pursue targeted collaborations-whether co-development, licensing, or commercial alliances-to access complementary capabilities in biologics, device engineering, or digital health. Such partnerships enable faster market entry, share development risk, and expand therapeutic ecosystems. Executing these recommendations will require cross-functional governance, clear KPIs, and staged investment to align R&D, commercial, and manufacturing objectives with evolving market realities.

Rigorous mixed-methods research approach combining clinical expert interviews, secondary literature synthesis, supply chain mapping, and scenario analysis for robust insights

This analysis synthesizes primary and secondary research disciplines to provide a robust and verifiable evidence base for strategic decisions. Primary research included structured consultations with clinical key opinion leaders in pulmonology and allergy, interviews with commercial executives across therapy and device segments, and discussions with procurement and payer representatives to capture reimbursement priorities and contracting trends. These engagements informed qualitative insights into clinician preferences, patient adherence drivers, and commercial decision-making frameworks.

Secondary research incorporated a comprehensive review of peer-reviewed clinical literature, regulatory guidance documents, and industry publications that describe therapeutic mechanisms, device performance characteristics, and safety considerations. Supply chain mapping and tariff classification analysis were used to identify points of vulnerability and to assess likely mitigation strategies. Triangulation of primary and secondary findings ensured consistency across clinical, commercial, and operational dimensions.

Analytical methods included comparative product positioning analysis, scenario planning for tariff and supply chain disruptions, and segmentation-driven assessment to align product attributes with end-user and distribution channel needs. Quality control measures included cross-validation of interview findings, source verification of regulatory and clinical references, and iterative expert review to refine conclusions. Together, these methods produce a defensible and actionable set of insights for stakeholders planning product development, market access, or strategic investment.

Executive synthesis emphasizing the need for integrated clinical evidence, device innovation, resilient supply chains, and regionally tailored access strategies

In sum, the asthma therapeutics arena presents a complex but navigable set of opportunities that hinge on aligning clinical innovation with pragmatic commercial and operational strategies. Biologic therapies have redefined care for severe phenotypes, while device and digital advancements are improving adherence and supporting new value-based models. However, external pressures such as payer scrutiny and trade-related tariff shifts require adaptive responses in evidence generation, supply chain design, and pricing strategies.

Successful stakeholders will be those who can integrate cross-disciplinary capabilities: developing robust real-world evidence programs, designing user-centric devices, and building resilient manufacturing footprints. Investments in partnerships-whether with device engineers, contract manufacturers, or regional distributors-will accelerate market entry and reduce execution risk. Moreover, tailoring strategies to regional regulatory and reimbursement landscapes will enhance access and commercial performance in diverse markets.

This conclusion underscores the imperative for coordinated action across R&D, commercial, and operations teams to translate scientific advances into sustainable patient impact and commercial returns. Organizations that adopt a proactive stance toward evidence, integration, and resilience will be best positioned to lead in the evolving asthma therapeutics ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Real-world evidence on long-term safety and efficacy of biologic therapies in severe eosinophilic asthma following expanded indications
  • 5.2. Integration of digital inhalers with telehealth platforms to improve adherence and monitoring in pediatric and adult asthma patients
  • 5.3. Development of small molecule CRTh2 receptor antagonists as novel oral therapies for moderate-to-severe asthma management
  • 5.4. Exploration of personalized asthma treatment algorithms incorporating genomic and biomarker profiling data for targeted biologic selection
  • 5.5. Advances in triple combination inhalers delivering ICS, LABA, and LAMA therapies for improved control in uncontrolled asthma populations
  • 5.6. Regulatory impact of recent FDA and EMA label expansions for tezepelumab and dupilumab on global asthma treatment strategies
  • 5.7. Emergence of anti-TSLP and anti-IL-25 pipeline candidates and their potential to redefine severe asthma therapeutic options

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Asthma Therapeutics Market, by Product Type

  • 8.1. Biologics
    • 8.1.1. Anti-Ige
    • 8.1.2. Anti-Il5
  • 8.2. Inhalers
    • 8.2.1. Dry Powder Inhalers
    • 8.2.2. Metered Dose Inhalers
    • 8.2.3. Soft Mist Inhalers
  • 8.3. Nebulizers
    • 8.3.1. Jet Nebulizers
    • 8.3.2. Mesh Nebulizers
    • 8.3.3. Ultrasonic Nebulizers
  • 8.4. Oral Drugs
    • 8.4.1. Leukotriene Modifiers
    • 8.4.2. Oral Corticosteroids
    • 8.4.3. Theophylline

9. Asthma Therapeutics Market, by Drug Class

  • 9.1. Beta Agonists
  • 9.2. Combination Therapies
  • 9.3. Inhaled Corticosteroids
  • 9.4. Leukotriene Modifiers
  • 9.5. Monoclonal Antibodies

10. Asthma Therapeutics Market, by Distribution Channel

  • 10.1. Clinics
    • 10.1.1. Home Care Settings
    • 10.1.2. Outpatient Clinics
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Asthma Therapeutics Market, by Route Of Administration

  • 11.1. Inhalation
    • 11.1.1. Aerosol
    • 11.1.2. Powder
  • 11.2. Oral
    • 11.2.1. Syrup Form
    • 11.2.2. Tablet Form
  • 11.3. Parenteral
    • 11.3.1. Intravenous
    • 11.3.2. Subcutaneous

12. Asthma Therapeutics Market, by End User

  • 12.1. Adult
  • 12.2. Geriatric
    • 12.2.1. 65-74 Years
    • 12.2.2. 75 Plus Years
  • 12.3. Pediatric
    • 12.3.1. 0-5 Years
    • 12.3.2. 6-12 Years

13. Asthma Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Asthma Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Asthma Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. AstraZeneca PLC
    • 16.3.3. Teva Pharmaceutical Industries Limited
    • 16.3.4. Novartis AG
    • 16.3.5. Sanofi S.A.
    • 16.3.6. Boehringer Ingelheim International GmbH
    • 16.3.7. Viatris Inc.
    • 16.3.8. Sunovion Pharmaceuticals Inc.
    • 16.3.9. Chiesi Farmaceutici S.p.A.
    • 16.3.10. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ASTHMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 326. NORTH AMERICA ASTHMA THERAPEU